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Does Slow and
Steady Win the Race?*
Jonathan G. Howlett, MD
Calgary, Alberta, Canada
Heart rate is 1 of the 4 vital signs that have provided a basis
for making medical decisions for centuries (1). In recent
years, we have learned that heart rate is also a powerful
predictor of outcomes in unselected populations, patients
with hypertension (2), and coronary artery disease, among
other conditions (3). In patients with systolic heart failure
(HF), higher heart rate at baseline and lower reduction of
heart rate from baseline to follow-up in response to beta
blockade are strong predictors of worse outcomes (4,5).
See page 1785
In this issue of the Journal, Castagno et al. (6) report on
the association of baseline heart rate with cardiovascular
outcomes in the CHARM (Candesartan in Heart failure:
Assessment of Reduction in Mortality and morbidity)
Program. In this multicenter, randomized, placebo-
controlled study, 7,599 patients with stable chronic HF
were enrolled into 1 of 3 subgroups before randomization, 1
of which allowed only patients with a resting left ventricular
ejection fraction (LVEF) 40%. The authors used baseline
heart rate obtained by either palpation or auscultation and a
concomitant 12-lead electrocardiogram to determine
whether the rhythm was sinus or atrial fibrillation (AF).
The outcomes included all-cause mortality (the primary
outcome of the study) and the composite cardiovascular
mortality plus hospital stay for worsening HF.
In the results, the authors provide us with 3 major
findings. First, they show that baseline resting heart rate is
associated with increased mortality, with every 10-beat/min
increase associated with respective increases of 8% for
all-cause mortality and 10% for the composite endpoint.
This perhaps unsurprising finding was not affected by
dosage or usage of beta-blocker or any other therapy and
serves to confirm similar findings previously made. Second,
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40% (nonsystolic HF), as we are shown that the relation-
ship between resting heart rate and adverse outcomes
continues irrespective of baseline LVEF. Third, and para-
doxically, we are shown that this association is not observed
in the 1,148 (15%) patients with AF at baseline. The
conclusions reported in this study are made in a well-
defined, well-treated group of patients with HF and so are
applicable to current medical practice.
Indeed, it is now a popular notion in HF guidelines that
optimal treatment of HF includes the use of beta-blocker
therapy to achieve a resting heart rate 60 beats/min or as
low as tolerated by the patient (7). Recent studies have
shown that administration of pure heart rate-lowering
medications to patients with chronic systolic HF and mildly
increased heart rate (70 beats/min at rest)—such as the
potassium channel blocker ivabradine—results in improve-
ment in ventricular reverse remodeling, improved symp-
toms, and fewer cardiovascular hospital stays (8,9). Al-
though undoubtedly effective, the precise mechanism(s)
underlying the benefit of beta-blockade for systolic HF
remain elusive. Studies to date have suggested the reduction
of baseline heart rate as well as follow-up heart rate on
therapy is predictive of beta-blocker efficacy (5). Perhaps
reduction of heart rate by beta-blocker therapy underpins
their beneficial effects, although other agents that reduce
resting heart rate have not shown efficacy. Perhaps careful
evaluation of other therapies that reduce heart rate, such as
ivabradine or vagal stimulation, should be tested in patients
not receiving beta-blockade.
The contrast in therapeutic evidence base between HF
patients with reduced versus preserved systolic function is
also noted when considering the issue of heart rate. Unlike
the former group, there is little information with regard to
the impact of heart rate and survival for those in the latter
group. Only 1 previous study, a subgroup analysis per-
formed in the DIG (Digitalis Investigator Group) study,
reported in their cohort with LVEF 45% a lack of
relationship between baseline heart rate and mortality (10).
his is in contrast to the current study, where the relation-
hip was similar to that in the overall trial. Why this
isagreement? The cohort in the DIG trial was smaller than
astagno et al. and did show a significant correlation with
F hospital stay. Perhaps the failure to find an association
ith mortality occurred in this lesser-powered cohort
hrough play of chance. Alternatively, a higher rate of usage
f digoxin in the DIG trial (50% by definition!) might have
layed a role. This study was undertaken before the current
ra of lower target serum digoxin levels, which might have
ed to higher rates of digoxin toxicity and propensity for
ethal arrhythmias, especially in women. Finally, the higher
ut point for LVEF (45% vs. 40%) might have influenced
he results in the 2 analyses. Other supporting data, such as
he robust positive association between resting heart rate in
variety of clinical settings as previously mentioned, suggest
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Nevertheless, other large data sources that include patients
with HF and preserved systolic function should be interro-
gated to determine the heart rate and outcome relationship.
After all, we have been surprised before where agents such
as angiotensin-converting enzyme inhibitors and beta
blockers exerted profoundly positive effects upon systolic
HF only to show a lack of similar effects in HF patients with
preserved ejection fraction. This might be yet another
reminder that, with all their similarities, the 2 forms of HF
retain fundamentally important differences.
Atrial fibrillation is an independent predictor of mortality
in patients with HF and is associated with other markers of
worse prognosis, such as history of hypertension, advanced
age, higher New York Heart Association functional classi-
fication, and lower ejection fraction (11). A major therapeu-
tic tenet is to control heart rate adequately in these patients,
with many clinicians ascribing a lower heart rate to thera-
peutic efficacy. On the surface then, Castagno et al. (6)
report the most intriguing and paradoxical finding in this
study—the lack of association of resting heart rate and
cardiovascular outcomes in the 15% of patients in this study
with AF. The authors themselves look closely at their data
and quite rightly suggest several reasons why this finding is
likely correct. First, the statistical interaction (p  0.001) is
ery indicative of a very strong interaction. Second, the
uthors’ own analysis suggests that patients with AF really
re different. Patients in sinus rhythm who were in the
ighest tertile of heart rate had lower ejection fraction and
igher New York Heart Association functional class and
ere more likely to be diabetic than those in the lower
ertiles. Among patients with AF, this was not seen.
dditionally, the authors point out that other smaller
ohorts have suggested there is no heart rate–outcome
elationship when AF is present. In contrast, it must be
ointed out that heart rate was determined by either
uscultation or palpation and might thus have been inaccu-
ate in those with AF (the so called “pulse deficit”) and so
ffected the analysis. It would be quite helpful, for purposes
f verification, to review the heart rate in patients with AF
y both electrocardiogram and physical exam to determine
hether there is likely an issue with pulse deficit. The
opulation of patients with implanted cardiac devices could
e an important source of information. The question of
eart rate and outcomes for patients in AF could be further
valuated—in fact expanded upon—with potential for anal-
sis of peak heart rate, temporal trends, and other factors
hat might instead predict outcomes for this subgroup.
Several potential explanations exist for this apparent
aradox. Patients with AF and lower heart rates might also
ave conduction system disease, which might be associated
ith worse prognosis. Secondly, such patients might have
oncomitant autonomic dysfunction or adrenergic stimula-
ion from impaired diastolic filling, with the need for a
esultant increase in heart rate for delivery of cardiac output.
n this scenario, those who are unable to increase theiratrioventricular conduction, perhaps due to beta receptor
down-regulation, will fare poorly in the long term. Atrial
fibrillation is notorious for its irregularity. Many patients
with uncontrolled AF also suffer periodic pauses, which
might result in syncopal or pre-syncopal symptoms (or, even
if asymptomatic, cause for clinician concern). This in turn
limits the amount of rate control that is tolerable. Recent
evidence suggests that the degree of heart rate irregularity
(as well as rate) and a measured “atrial fibrillatory rate”
might impact outcomes in AF (the more irregular, the
worse the outcome) (12). This might serve as a marker of
the overall conductive and autonomic state or a driver of
outcomes. One potential therapeutic option then might be
to ablate the atrioventricular node and place a pacemaker (or
biventricular pacemaker) to control heart rate. This strategy,
perhaps combined with AF ablation, is under consideration
as a trial in the stable systolic HF population.
Castagno et al. (6) have provided us with important
confirmatory, expansive, and surprising data in the field of
heart rate and outcomes, and for that they should be
congratulated. From this further questions arise. For exam-
ple, can pure heart rate reduction be as efficacious as beta
blockade in patients with systolic HF? Will heart rate
reduction in patients with nonsystolic HF reduce morbidity
and mortality? Will this strategy work for patients with
cardiovascular disease but without HF? For now, slow and
steady wins the race for most patients with HF and sinus
rhythm, but for those with AF, the race is far from over.
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